Discovering breakthroughs in fibrosis and neurodegeneration
Blade Therapeutics is advancing a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains for the potential treatment of lung, liver and cardiac fibrosis or neurodegenerative diseases. Since the company’s founding in 2015, Blade has used a combination of in-house drug research and selective in-licensing to build a risk-diversified pipeline.
Our focused approach offers the potential to produce disease-modifying, life-saving therapies.
1 Autotaxin Inhibitor
2 Calpain Inhibitor
3 Idiopathic Pulmonary Fibrosis
4 Systemic Sclerosis – Interstitial Lung Disease
Poster: Differentiating Characteristics of Cudetaxestat (BLD-0409), a Non-Competitive Autotaxin Inhibitor Under Development for Idiopathic Pulmonary Fibrosis.
Wong et al, American Thoracic Society 2022 International Conference, May 18, 2022.
Poster: Preclinical Evaluation of Cudetaxestat (BLD-0409) for Potential Drug-Drug Interactions (DDI’s).
Yu et al, American Thoracic Society 2022 International Conference, May 16, 2022.
Poster: Clinical Evaluation of Cudetaxestat for Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Potential Drug-Drug Interactions.
Mody et al, American Thoracic Society 2022 International Conference, May 16, 2022.
Poster: Preclinical Evaluation of Cudetaxestat (BLD-0409) for Potential Drug-Drug Interactions
Yu et al., Society of Toxicology 61st Annual Meeting and ToxExpo, San Diego, March 30, 2022.
A Novel Calpain Inhibitor Compound Has Protective Effects on a Zebrafish Model of Spinocerebellar Ataxia Type 3
Robinson et al., Cells 2021, 10, 2592
Calpain 9 as a therapeutic target in TGFβ-induced mesenchymal transition and fibrosis
Kim et al., Sci. Transl. Med. 11, July 2019